AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16973659
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg intravitreal triamcinolone (ivTA)
Trial: 15718403
Drug: Microgravity (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microgravity (0 G)
Trial: 15718403
Drug: Hypergravity (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypergravity (1.8 G)
Trial: 15718403
Drug: Normal gravity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal gravity (1 G)
Trial: 15718403
Drug: Hypergravity (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypergravity (1.7 G)
Trial: 12111110
Drug: Fludarabine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine treatment (25 mg/m² daily for 5 days every 28 days)
Trial: 10502181
Drug: Contrast-enhanced EUS
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced EUS with air-filled albumin (0.22 mL/kg) intravenously injected at a rate of 1 mL/sec for 10 minutes
Trial: 7560251
Drug: Dolasetron (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron (0.6 to 5.0 mg/kg)
Trial: 7560251
Drug: Dolasetron (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron (doses > or = 3.0 mg/kg)
Trial: 31274484
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion (15 mg/kg) started 20 min before induction, during surgery, and for the first postoperative 24 hours.
Trial: 31274484
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate infusion (15 mg/kg).
Trial: 28599889
Drug: Thiopentone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (7.5 mg kg−1)
Trial: 28599889
Drug: Propofol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (3 mg kg−1)
Trial: 28599889
Drug: Alfaxalone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone (1.5 mg kg−1)
Trial: 8633935
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triiodothyronine (T3) treatment
Trial: 1533530
Drug: terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine 120 mg
Trial: 3880657
Drug: Vincristine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (0.4 mg/m2/1/day by continuous infusion)
Trial: 3880657
Drug: Vinblastine (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinblastine (1.7 mg/m2/1/day by continuous infusion)
Trial: 3880657
Drug: Vindesine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (1.2 mg/m2/1/day by continuous infusion)
Trial: 3880657
Drug: Vindesine (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (1.2 mg/m2/1/day intermittent bolus)
Trial: 29511334
Drug: D-amphetamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (20 mg oral)
Trial: 29511334
Drug: Methamphetamine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (20 mg oral)
Trial: 25944519
Drug: Combination 17β-estradiol/progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination 17β-estradiol/progesterone capsule
Trial: 16492849
Drug: Programmed Intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed Intermittent Epidural Bolus (PIEB) - 6 mL bolus every 30 min starting 45 min after intrathecal injection
Trial: 16492849
Drug: Continuous Epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Epidural Infusion (CEI) - 12 mL/h infusion starting 15 min after intrathecal injection
Trial: 7818648
Drug: Bendrofluazide 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 1.25 mg and 5.0 mg
Trial: 2453895
Drug: Hydromorphone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (6 mg)
Trial: 2453895
Drug: Naloxone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.2 mg)
Trial: 2453895
Drug: Buprenorphine 0.2
RxNorm normalized name: buprenorphine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.2 mg plus Naloxone 0.2 mg
Trial: 2453895
Drug: Buprenorphine 0.3
RxNorm normalized name: buprenorphine 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.3 mg plus Naloxone 0.2 mg
Trial: 27011262
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 0.25 mg/0.01 ml
Trial: 27011262
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 0.625 mg/0.025 ml
Trial: 27978532
Drug: Ibuprofen 200mg
RxNorm normalized name: IBUPROFEN 200MG CAP
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200mg plus paracetamol 325mg TID
Trial: 27978532
Drug: Ibuprofen 400mg
RxNorm normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400mg TID
Trial: 25969894
Drug: MenABCWY formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenABCWY formulations containing OMV components
Trial: 25969894
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of OMV‐containing MenABCWY formulations
Trial: 22244384
Drug: Bio‐Oss Collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio‐Oss Collagen with implant placement (Group 1)
Trial: 22244384
Drug: Bio‐Oss Collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio‐Oss Collagen without implant placement (Group 2)
Trial: 10480420
Drug: MMF-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, n=50)
Trial: 10480420
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CsA-Neoral and steroids, n=50)
Trial: 7681647
Drug: Rapid antigen
RxNorm normalized name: INDICAID COVID-19 Rapid Antigen Home Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid antigen detecting test and a 10-day oral penicillin course
Trial: 7681647
Drug: Rapid antigen
RxNorm normalized name: INDICAID COVID-19 Rapid Antigen Home Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid antigen detecting test and intramuscular benzathin penicillin G
Trial: 7681647
Drug: Intramuscular benzathin
RxNorm normalized name: Benzaclin
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular benzathin penicillin G for all children with pharyngitis
Trial: 26288118
Drug: mirabegron 50
RxNorm normalized name: mirabegron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirabegron 50 mg/day
Trial: 26288118
Drug: tolterodine ER
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine ER 4 mg/day
Trial: 24899242
Drug: Mindfulness training
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness training program (weekly group-based classes in mindfulness practice, 2 ½ hours, for 8 weeks plus a 7-hour Saturday session in Week 6)
Trial: 22235059
Drug: Action observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action observation (EG) - watching video footage of daily routine tasks and imitating movements for 2 minutes with therapist assistance.
Trial: 15782753
Drug: Prescription for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription for nicotine patches
Trial: 7577208
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus etoposide (standard chemotherapy)
Trial: 3083100
Drug: Hyperventilation at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperventilation at normal rate and tidal volume of 1.5 l
Trial: 3083100
Drug: Hyperventilation at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperventilation at rate 24/min and tidal volume of 1.5 l
Trial: 3083100
Drug: Hyperventilation at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperventilation at rate 24/min and tidal volume of 1.4 l
Trial: 30251010
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (120 mg/day)
Trial: 28081351
Drug: Methylprednisolone 5
RxNorm normalized name: methylprednisolone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 5 mg/kg
Trial: 22162533
Drug: Istradefylline (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istradefylline (20 to 40 mg/d)
Trial: 22162533
Drug: Istradefylline (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istradefylline (40 mg/d)
Trial: 22162533
Drug: Istradefylline (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Istradefylline (dose increase)
Trial: 18555813
Drug: Drospirenone 3
RxNorm normalized name: drospirenone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 3 mg / Ethinylestradiol 20 mcg in a 24/4 regimen
Trial: 15756154
Drug: Epidural administration
RxNorm normalized name: epidural administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural administration of naropina 0.2%+fentanyl 4 microg/mL by elastomeric pump (rate 5 ml/h)
Trial: 15756154
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of tramadol 600 mg+ketorolac trometamina 120 mg+ranitidina 200 mg+ondansetron 16 mg by elastomeric pump (rate 5 ml/h for 48 hours)
Trial: 12427649
Drug: simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin plus 600 mg/d vitamin E
Trial: 10320598
Drug: Paracetamol elixir
RxNorm normalized name: Soul Pattinson Childrens Paracetamol Elixir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol elixir (40 mg x kg(‐1)) 90 min before surgery
Trial: 10320598
Drug: Paracetamol suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol suppositories (40 mg x kg(‐1)) intraoperatively
Trial: 7588352
Drug: Fluconazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (3 mg/kg/daily per os)
Trial: 7588352
Drug: Flucytosine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flucytosine (100 mg/kg/daily per os)
Trial: 30957170
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of grazoprevir/elbasvir therapy
Trial: 30957170
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of grazoprevir/elbasvir therapy
Trial: 30957170
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of grazoprevir/elbasvir therapy with high HCV-1b load (≥1,500,000 IU/mL)
Trial: 30957170
Drug: 8 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 weeks of grazoprevir/elbasvir therapy with baseline Y93H RAS frequency >15%
Trial: 30957170
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of grazoprevir/elbasvir therapy with high HCV-1b load and baseline Y93H RAS frequency >15%
Trial: 26596997
Drug: Family Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Therapy with Family Meal Intervention (FTFM)
Trial: 26596997
Drug: Family Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family Therapy without Family Meal Intervention (FT)
Trial: 23420115
Drug: Theobromine 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine 250 mg
Trial: 23420115
Drug: Theobromine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine 500 mg
Trial: 23420115
Drug: Theobromine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine 1000 mg
Trial: 21536693
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to monotherapy
Trial: 19401662
Drug: Increased tidal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased tidal volume (from 6 to 10 ml kg(‐1))
Trial: 16963248
Drug: High-dose purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose purified soy isoflavones (genistein, 558 mg/day; daidzein, 296 mg/day; glycitein, 44 mg/day) for 84 days
Trial: 16963248
Drug: High-dose purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose purified soy isoflavones
Trial: 15783119
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 300 mg with pyridoxine 20 mg daily for 1 year or until TB development
Trial: 7873469
Drug: Beta-blockers or
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers or calcium antagonists (used in association with nitrates)
Trial: 3348157
Drug: Multivitamin-mineral supplement
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin-mineral supplement providing 0.5 mg/d vitamin B-6
Trial: 28442892
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg orodispersible film
Trial: 28442892
Drug: Film-coated 100
RxNorm normalized name: flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated 100 mg tablet (Viagra®)
Trial: 25487006
Drug: Manual pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual pressure before benzathine penicillin injection
Trial: 20887742
Drug: Protein-rich supplements
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-rich supplements (80±21g protein intake)
Trial: 20887742
Drug: Isoenergetic combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoenergetic combination of carbohydrate and fat supplements (59±11g protein intake)
Trial: 20887742
Drug: Protein-rich supplements
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-rich supplements
Trial: 20887742
Drug: Isoenergetic combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoenergetic combination of carbohydrate and fat supplements
Trial: 14508205
Drug: Lercanidipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine (20 mg daily)
Trial: 8619389
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus UFT (400 mg/day: group B)
Trial: 8619389
Drug: Estrogen alone
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen alone (Honvan 200 mg/day or presexol 1 mg/day: group A)
Trial: 4015740
Drug: Suprofen 200
RxNorm normalized name: suprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprofen 200 mg/ml i.m. (3 injections/day for 7 days)
Trial: 4015740
Drug: Diclofenac 25
RxNorm normalized name: diclofenac 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 25 mg/ml i.m. (3 injections/day for 7 days)
Trial: 4015740
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 injections/day for 7 days)
Trial: 31272477
Drug: Antipsychotics (APs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics (APs) alone
Trial: 31272477
Drug: Psychological Interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological Interventions (PI) alone (Cognitive Behavioural Therapy and Family Intervention)
Trial: 31272477
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Antipsychotics and Psychological Interventions
Trial: 30058395
Drug: Dialectical Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavioral Therapy‐Corrections Modified (DBT‐CM)
Trial: 26863321
Drug: Yoga practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga practice frequency after treatment
Trial: 22157329
Drug: Acotiamide 100
RxNorm normalized name: acetiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acotiamide 100 mg three times a day for 4 weeks
Trial: 22157329
Drug: Acotiamide 100
RxNorm normalized name: acetiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acotiamide 100 mg
Trial: 15816570
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 3 mL demand dose with 6 min lockout interval
Trial: 15816570
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 6 mL demand dose with 12 min lockout interval
Trial: 15816570
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 9 mL demand dose with 18 min lockout interval
Trial: 12774848
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (400 mL, 279.6 mg total anthocyanins)
Trial: 12774848
Drug: Red grape
RxNorm normalized name: CVS Children's Cold & Cough Elixir (Red Grape)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red grape juice (400 mL, 283.5 mg total anthocyanins)
Trial: 10563230
Drug: Prophylactic drugs
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic drugs (metoprolol, divalproex, amitriptyline, atenolol, flunarizine, naproxen)
Trial: 8740095
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cefpodoxime proxetil (reference)
Trial: 8740095
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg cefpodoxime and 200 mg acetylcysteine (test)
Trial: 24147869
Drug: On-demand alverine
RxNorm normalized name: alverine
DrugBank: Alverine (DB01616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand alverine citrate/simeticone (ACS) treatment
Trial: 24147869
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (mainly antispasmodics)
Trial: 15574551
Drug: Aprotinin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (2 x 10(6) KIU loading dose, 2 x 10(6) KIU added to circuit prime, continuous infusion of 5 x 10(5) KIU/hr)
Trial: 9832483
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet (rich in fruits, vegetables, and low-fat dairy products, reduced in fat)
Trial: 8126691
Drug: Disclosure induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disclosure induction (three weekly 20-min individual sessions discussing a stressful topic)
Trial: 412099
Drug: Trimethoprim-sulfamethoxazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (150 mg of trimethoprim and 750 mg of sulfamethoxazole per square meter per day)
Trial: 27836905
Drug: Continuous femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous femoral nerve block (CFNB) with ropivacaine infusion for 2 days and oxycodone
Trial: 27836905
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesic (IV PCA) of morphine
Trial: 19928391
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg of MDMA
Trial: 15217028
Drug: Telephone-based problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based problem-solving therapy
Trial: 12539568
Drug: Propofol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.1 mg.kg‐1.min‐1)
Trial: 9416719
Drug: Patient-controlled interscalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled interscalene analgesia (PCIA) with 0.15% bupivacaine, continuous infusion at 5 ml/h plus bolus of 3 or 4 ml with a lock-time of 20 min.
Trial: 9416719
Drug: Intravenous patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient-controlled analgesia (PCA) with nicomorphine, continuous infusion at 0.5 mg/h plus bolus of 2 or 3 mg with a lock-time of 20 min.
Trial: 3815837
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose Bupivacaine (50 mg)
Trial: 3815837
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose Bupivacaine (25 mg)
Trial: 3815837
Drug: Oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administration during the block
Trial: 3815837
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of Bupivacaine
Trial: 18089634
Drug: Pamidronate 12
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 12 mg/kg/year